Trial Profile
A Phase 1/1b Open Label, Multi-center Exploratory Study to Investigate the Bioactivity, Ocular and Systemic Safety, Tolerability, and Pharmacokinetics Following Single and Multiple Intravitreal Administrations of KSI-301 in Subjects With Wet Age-Related Macular Degeneration (wAMD), Diabetic Macular Edema (DME) and Retinal Vein Occlusion (RVO)
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 22 Mar 2024
Price :
$35
*
At a glance
- Drugs Tarcocimab tedromer (Primary)
- Indications Diabetic macular oedema; Retinal vein occlusion; Wet age-related macular degeneration
- Focus Adverse reactions; Proof of concept
- Sponsors Kodiak Sciences
- 15 Jun 2022 Status changed from active, no longer recruiting to discontinued.
- 31 Aug 2021 Planned End Date changed from 1 Jan 2022 to 1 Jan 2023.
- 31 Aug 2021 Planned primary completion date changed from 1 Jun 2021 to 1 Jan 2023.